Loss of BCAP31 or POLR1E Accelerates Aging in C. elegans and is Linked to Senescence in Vascular Endothelium.
Key claim: BCAP31 and POLR1E are evolutionarily conserved CD44-associated protectors against cellular senescence and organismal aging; their loss shortens C. elegans lifespan and drives premature senescence in human vascular endothelium.
Abstract
Aging involves the progressive decline of cellular function, yet the key molecular regulators that determine aging require further identification. Building on our previous finding that the intracellular domain of CD44 (CD44ICD) is a critical aging regulator, we performed an interactome screen to identify its functional partners. This approach revealed BCAP31 and POLR1E as two previously unrecognized modulators of senescence. Depletion of their respective orthologs in Caenorhabditis elegans (C. elegans) shortened lifespan and accelerated age-related functional decline. In human vascular endothelial cells, knockdown of BCAP31 or POLR1E induced premature cellular senescence, whereas their overexpression countered it. Importantly, the protein levels of both BCAP31 and POLR1E decreased during physiological aging across species, including in senescent endothelial cells, aged nematodes, and tissues from old mice, with BCAP31 reduction being particularly pronounced in the cardiovascular system. Our findings establish BCAP31 and POLR1E as evolutionarily conserved components of a CD44-associated network that protects against cellular senescence and organismal aging, highlighting new potential targets for mitigating age-related vascular decline.
Why this matters
Most senescence-modifier screens rediscover known DDR/SASP nodes; BCAP31 (an ER membrane protein) and POLR1E (an RNA Pol I subunit) implicate ER proteostasis and ribosomal RNA transcription as CD44-linked upstream regulators of endothelial senescence, connecting the hallmark to organelle-specific machinery not previously prioritized. The cross-species pattern (worm lifespan, human endothelium, aged mouse cardiovascular tissue) is suggestive but preclinical; whether restoring BCAP31 or POLR1E in aged vasculature yields functional benefit remains untested.